ENTO - enterothera.com Trailing Twelve Months Revenue Growth

Public company logo of Entero Therapeutics Inc. (ENTO)

Entero Therapeutics, Inc. (ENTO) develops enzyme-based treatments to combat celiac disease, establishing a comprehensive therapy system for digestive pathologies. However, the lack of recurring revenue and the costs associated with clinical trials are creating a liquidity deficit. The relative change in trailing twelve-month revenue compared to the same period last year confirms these data, with the current level standing at 0.00, reflecting the reaction of commercial volumes to external market shifts.

ENTO - Entero Therapeutics Sales Growth YoY (Last Twelve Months) over the range 11/23/2025 - 12/01/2025

Entero Therapeutics - analytical breakdowns and key metrics (ENTO)

- current price and projected stock value:
Summary company analytics:enterothera.com
Brand item of enterothera.com

Entero Therapeutics, Inc. (ENTO) focuses on developing innovative therapies for patients with gastrointestinal pathologies, making the annual trend of sales revenue over four quarters a key indicator of its asset commercialization. This metric measures the market consensus of the value of goods sold over a rolling year on a daily basis, allowing investors to strip away accounting distortions and objectively assess the real demand for the company's drugs.